268 related articles for article (PubMed ID: 33288854)
1. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression.
Di Domenico A; Pipinikas CP; Maire RS; Bräutigam K; Simillion C; Dettmer MS; Vassella E; Thirlwell C; Perren A; Marinoni I
Commun Biol; 2020 Dec; 3(1):740. PubMed ID: 33288854
[TBL] [Abstract][Full Text] [Related]
2. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.
Simon T; Riemer P; Jarosch A; Detjen K; Di Domenico A; Bormann F; Menne A; Khouja S; Monjé N; Childs LH; Lenze D; Leser U; Rossner F; Morkel M; Blüthgen N; Pavel M; Horst D; Capper D; Marinoni I; Perren A; Mamlouk S; Sers C
Genome Med; 2022 Mar; 14(1):24. PubMed ID: 35227293
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.
Kajtazi Y; Kaemmerer D; Sänger J; Schulz S; Lupp A
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2481-2493. PubMed ID: 31451931
[TBL] [Abstract][Full Text] [Related]
8. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.
Hong X; Qiao S; Li F; Wang W; Jiang R; Wu H; Chen H; Liu L; Peng J; Wang J; Jia C; Liang X; Dai H; Jiang J; Zhang T; Liao Q; Dai M; Cong L; Han X; Guo D; Liang Z; Li D; Zheng Z; Ye C; Li S; Zhao Y; Wu K; Wu W
Gut; 2020 May; 69(5):877-887. PubMed ID: 31462556
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
Marini F; Giusti F; Brandi ML
Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
[TBL] [Abstract][Full Text] [Related]
10. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT).
Neyaz A; Crotty R; Rickelt S; Pankaj A; Stojanova M; Michelakos TP; Sekigami Y; Kontos F; Parrack PH; Patil DT; Heaphy CM; Ferrone CR; Deshpande V
Histopathology; 2023 Oct; 83(4):546-558. PubMed ID: 37455385
[TBL] [Abstract][Full Text] [Related]
11. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
[TBL] [Abstract][Full Text] [Related]
12. Identification of new candidate genes and signalling pathways associated with the development of neuroendocrine pancreatic tumours based on next generation sequencing data.
Kit OI; Trifanov VS; Petrusenko NA; Gvaldin DY; Kutilin DS; Timoshkina NN
Mol Biol Rep; 2020 Jun; 47(6):4233-4243. PubMed ID: 32451928
[TBL] [Abstract][Full Text] [Related]
13. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
14. Dictating genomic destiny: Epigenetic regulation of pancreatic neuroendocrine tumours.
Gundara JS; Jamal K; Kurzawinski T
Mol Cell Endocrinol; 2018 Jul; 469():85-91. PubMed ID: 28385665
[TBL] [Abstract][Full Text] [Related]
15. Hypo-methylation mediates chromosomal instability in pancreatic NET.
Marinoni I; Wiederkeher A; Wiedmer T; Pantasis S; Di Domenico A; Frank R; Vassella E; Schmitt A; Perren A
Endocr Relat Cancer; 2017 Mar; 24(3):137-146. PubMed ID: 28115389
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.
Takano Y; Kasai K; Takagishi Y; Kikumori T; Imai T; Murata Y; Hayashi Y
PLoS One; 2015; 10(7):e0133812. PubMed ID: 26192435
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization.
Capodanno Y; Chen Y; Schrader J; Tomosugi M; Sumi S; Yokoyama A; Hiraoka N; Ohki R
Neoplasia; 2021 Sep; 23(9):979-992. PubMed ID: 34352404
[TBL] [Abstract][Full Text] [Related]
18. Expression of estrogen-induced genes and estrogen receptor β in pancreatic neuroendocrine tumors: implications for targeted therapy.
Estrella JS; Ma LT; Milton DR; Yao JC; Wang H; Rashid A; Broaddus RR
Pancreas; 2014 Oct; 43(7):996-1002. PubMed ID: 25058880
[TBL] [Abstract][Full Text] [Related]
19. PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
Ohki R; Saito K; Chen Y; Kawase T; Hiraoka N; Saigawa R; Minegishi M; Aita Y; Yanai G; Shimizu H; Yachida S; Sakata N; Doi R; Kosuge T; Shimada K; Tycko B; Tsukada T; Kanai Y; Sumi S; Namiki H; Taya Y; Shibata T; Nakagama H
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):E2404-13. PubMed ID: 24912192
[TBL] [Abstract][Full Text] [Related]
20. ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup.
Chan CS; Laddha SV; Lewis PW; Koletsky MS; Robzyk K; Da Silva E; Torres PJ; Untch BR; Li J; Bose P; Chan TA; Klimstra DS; Allis CD; Tang LH
Nat Commun; 2018 Oct; 9(1):4158. PubMed ID: 30315258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]